Jennifer M Spangle

Dr. Jennifer M Spangle

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
RLRichard Lee
Richard Lee
KSKirti Sad
Kirti Sad
DFDorelle V. Fawwal
Dorelle V. Fawwal
JSJennifer M Spangle
Jennifer M Spangle
Breast cancer pathogenesis, treatment, and patient outcomes are shaped by tumor-intrinsic genomic alterations that divide breast tumors into molecular subtypes. These molecular subtypes often dictate viable therapeutic interventions and, ultimately, patient outcomes. However, heterogeneity in therapeutic response may be a result of underlying epigenetic features that may further stratify breast cancer patient outcomes. In this review, we examine non-genetic mechanisms that drive functional changes to chromatin in breast cancer to contribute to cell and tumor fitness and highlight how epigenetic activity may inform the therapeutic response. We conclude by providing perspectives on the future of therapeutic targeting of epigenetic enzymes, an approach that holds untapped potential to improve breast cancer patient outcomes.

14 September 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JSJennifer M Spangle
Jennifer M Spangle
TVThanh Von
Thanh Von
DPDean C. Pavlick
Dean C. Pavlick
AKArina Khotimsky
Arina Khotimsky
JZJean J. Zhao
Jean J. Zhao
TRThomas M. Roberts
Thomas M. Roberts
Significance: While PIK3CA hotspot mutations frequently occur in solid cancers and in some contexts are therapeutically actionable, numerous other PIK3CA genomic alterations have been observed but remain uncharacterized. The authors identify C-terminal PIK3CA frameshift mutations as oncogenic driver events dependent on p85 binding in breast cancer and other cancers. Breast cell lines and tumors expressing PIK3CA frameshift mutations are sensitive to PI3K inhibition via alpelisib treatment. Patients with tumors characterized by these mutations may derive clinical benefit from p110α-selective inhibition.

8 April 2024 in Journal of the American Chemical Society
Verified
Journal Article
Open access
BEBenjamin Emenike
Benjamin Emenike
PCPatrick Czabala
Patrick Czabala
JFJonathan Farhi
Jonathan Farhi
JSJagannath Swaminathan
Jagannath Swaminathan
EAEric Anslyn
Eric Anslyn
MRMonika Raj
Monika Raj
Lysine dimethylation (Kme(2)) is a crucial post-translational modification (PTM) that regulates biological processes and is implicated in diseases. There is significant interest in globally identifying these methylation marks. Unfortunately, this remains challenging due to the lack of robust technologies for selectively labeling Kme(2). To address this, we present a chemical method named tertiary amine coupling by oxidation (TACO). This method selectively modifies Kme(2) to aldehydes using Selectfluor and a base. The resulting aldehydes from Kme(2) were then functionalized using reductive amination, thiolamine, and oxime chemistry. We successfully demonstrated the versatility of TACO in selectively labeling Kme(2) peptides and proteins in complex cell lysate mixtures with varying payloads, including affinity tags and fluorophores. We further showed the application of TACO chemistry for the identification of Kme(2) sites at a single-molecule level by fluorosequencing. We discovered novel 30 Kme(2) sites, in addition to previously known 5 Kme(2) sites, by proteomics analysis of TACO-modified nuclear extracts. Our work establishes a unique strategy for covalently modifying Kme(2), facilitating the global identification of low-abundance Kme(2)-PTMs and their sites within complex cell lysate mixtures.

19 July 2023 in Chemical Science
Verified
Journal Article
Open access
PDF file
RWRachel Wills
Rachel Wills
JFJonathan Farhi
Jonathan Farhi
PCPatrick Czabala
Patrick Czabala
SSSophia Shahin
Sophia Shahin
JSJennifer M Spangle
Jennifer M Spangle
MRMonika Raj
Monika Raj
Aliphatic aldehydes are reactive electrophilic carbonyls that cross-link with DNA and proteins leading to cellular toxicity and disease pathogenesis. This toxicity is due to the cooperative effect of multiple aldehydes via a common mechanism. Therefore, live-cell imaging of total aliphatic aldehydes, small-to-long chain (C1–C10), is highly desired to decipher their physiological and pathological functions. However, sensors for imaging total cellular aliphatic aldehydes are currently lacking despite their high concentrations (∼80 to >500 μM) inside cells. Herein, we report chemical sensors that generate a benzimidazole moiety upon reaction with aliphatic aldehydes of different chain lengths (C1–C10), resulting in turn-on fluorescence. These sensors exhibit high quantum yields, high dynamic range, and enable the quantification of changes in both the exogenous administration of aldehydes and endogenous real-time formation of aliphatic aldehydes in live mammalian cells. This tool has great potential to transform aldehyde research by illuminating cellular metabolites that have remained elusive in living systems.

14 May 2022 in G3: Genes, Genomes, Genetics
Verified
Journal Article
Open access
PDF file
LLLaramie D Lemon
Laramie D Lemon
SKSneha Kannan
Sneha Kannan
KMKim Wai Mo
Kim Wai Mo
MAMiranda Adams
Miranda Adams
HCHaley G Choi
Haley G Choi
ACAnita H Corbett
Anita H Corbett
Somatic missense mutations in histone genes turn these essential proteins into oncohistones, which can drive oncogenesis. Understanding how missense mutations alter histone function is challenging in mammals as mutations occur in a single histone gene. For example, described oncohistone mutations predominantly occur in the histone H3.3 gene, despite the human genome encoding 15 H3 genes. To understand how oncogenic histone missense mutations alter histone function, we leveraged the budding yeast model, which contains only 2 H3 genes, to explore the functional consequences of oncohistones H3K36M, H3G34W, H3G34L, H3G34R, and H3G34V. Analysis of cells that express each of these variants as the sole copy of H3 reveals that H3K36 mutants show different drug sensitivities compared to H3G34 mutants. This finding suggests that changes to proximal amino acids in the H3 N-terminal tail alter distinct biological pathways. We exploited the caffeine-sensitive growth of H3K36-mutant cells to perform a high copy suppressor screen. This screen identified genes linked to histone function and transcriptional regulation, including Esa1, a histone H4/H2A acetyltransferase; Tos4, a forkhead-associated domain-containing gene expression regulator; Pho92, an N6-methyladenosine RNA-binding protein; and Sgv1/Bur1, a cyclin-dependent kinase. We show that the Esa1 lysine acetyltransferase activity is critical for suppression of the caffeine-sensitive growth of H3K36R-mutant cells while the previously characterized binding interactions of Tos4 and Pho92 are not required for suppression. This screen identifies pathways that could be altered by oncohistone mutations and highlights the value of yeast genetics to identify pathways altered by such mutations.

11 December 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
XZXINRAN ZHANG
XINRAN ZHANG
DFDorelle V. Fawwal
Dorelle V. Fawwal
JSJennifer M Spangle
Jennifer M Spangle
ACAnita H Corbett
Anita H Corbett
CJCelina Yvonne Jones
Celina Yvonne Jones
Understanding the molecular basis of cancer initiation and progression is critical in developing effective treatment strategies. Recently, mutations in genes encoding histone proteins that drive oncogenesis have been identified, converting these essential proteins into “oncohistones”. Understanding how oncohistone mutants, which are commonly single missense mutations, subvert the normal function of histones to drive oncogenesis requires defining the functional consequences of such changes. Histones genes are present in multiple copies in the human genome with 15 genes encoding histone H3 isoforms, the histone for which the majority of oncohistone variants have been analyzed thus far. With so many wildtype histone proteins being expressed simultaneously within the oncohistone, it can be difficult to decipher the precise mechanistic consequences of the mutant protein. In contrast to humans, budding and fission yeast contain only two or three histone H3 genes, respectively. Furthermore, yeast histones share ~90% sequence identity with human H3 protein. Its genetic simplicity and evolutionary conservation make yeast an excellent model for characterizing oncohistones. The power of genetic approaches can also be exploited in yeast models to define cellular signaling pathways that could serve as actionable therapeutic targets. In this review, we focus on the value of yeast models to serve as a discovery tool that can provide mechanistic insights and inform subsequent translational studies in humans.